Oneonta woman leads statewide realty association
An Oneonta real estate broker is now the president of a statewide association.
Jacqlene Rose, a licensed associate real estate broker at Coldwell Banker Timberland Properties' Sidney office, was sworn in as the president of the New York State Association of Realtorsduring the NYSAR Mid-Winter Business Meetings in Albany, according to a news release.
Rose, who is a member of the Rose Team, which includes 17 agents from the Sidney and Oneonta offices, "has been a driving force in the local real estate market and beyond," the release stated.
'I am truly honored to have the opportunity to serve as the president of the New York State Association of Realtors and its 61,000 members,' Rose said. 'This is a pivotal moment for real estate in our state, and I look forward to continuing the work of strengthening our industry, elevating our profession and advocating for policies that will benefit real estate professionals and consumers alike.'
Rose "has been an advocate for professional growth, education and ethics in the industry for over three decades," the release stated. "Under her leadership, the Rose Team has been consistently recognized for its dedication to clients, providing top-tier services, and fostering a culture of collaboration and success."
As NYSAR president, Rose "will be at the forefront of advocating for policies that promote a vibrant real estate market, while also championing the professional development of agents across New York state," according to the release. "Her vision for the association includes creating more opportunities for agents to grow and thrive, addressing emerging industry challenges and ensuring that consumers have access to knowledgeable, ethical professionals."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
dōTERRA Healing Hands Celebrates 15 Years of Impact
The Nonprofit Has Empowered Tens of Thousands of Individuals and Communities Globally Since Its Founding PLEASANT GROVE, Utah , June 10, 2025 /PRNewswire/ -- dōTERRA Healing Hands celebrates 15 years of impact this June, having donated over $55 million to empower communities worldwide. A private virtual event will bring together donors to reflect on the impact their charitable contributions have made, particularly in Bulgaria where dōTERRA sources Rose essential oil. The foundation will also commemorate the milestone with social media giveaways and a celebration of the many projects that have changed and improved the lives of individuals and communities. Rose essential oil is of particular importance to the foundation because dōTERRA donates the purchase price (net of tax) of each dōTERRA spa Rose Hand Lotion to the dōTERRA Healing Hands Foundation®.* These funds have helped make a difference in places like Bulgaria, where dōTERRA Healing Hands funded a mobile blood donation clinic to address a critical shortage. This clinic serves the Rose Valley community, where dōTERRA sources and distills its Rose essential oil. "The dōTERRA Healing Hands Foundation has transformed lives and communities worldwide, creating a ripple effect of positive change. Our projects not only uplift those directly served but also empowers the volunteers and organizers who bring them to life," said Misty Bond, Vice President of Corporate Relations and Philanthropy. "Witnessing the dedication of our global community fills me with gratitude. As we look ahead, I am confident that the next 15 years will bring even more inspiring stories and life-changing initiatives to those who need it most." Help dōTERRA meets its goal of selling 15,000 dōTERRA spa Rose Hand Lotions and make a lasting impact in communities around the world.* Follow dōTERRA Healing Hands on Instagram to enter giveaways and additional ways to celebrate this special anniversary. About dōTERRA dōTERRA International is an integrative health and wellness company and the world leader in the global aromatherapy and essential oils market. dōTERRA sources, tests, manufactures, and distributes CPTG Certified Pure Tested Grade® essential oils and essential oil products to over 10 million Wellness Advocates and customers. Through its new Wellness Made Simple program—dōTERRA's science-backed approach to laying a strong wellness foundation—the company empowers individuals to take charge of their health. Like and follow dōTERRA on Facebook and Instagram. Learn more at *About the dōTERRA Healing Hands Foundation The dōTERRA Healing Hands Foundation, a registered 501(c)(3) nonprofit organization, offers resources and tools to global sourcing communities and charitable organizations supporting self-reliance, healthcare, education, clean water, and more. To learn more about the dōTERRA Healing Hands Foundation, visit View original content to download multimedia: SOURCE doTERRA International, LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
Market House gets its doors
Thanks to a $44,000 grant award announced in the midst of the 155th anniversary of its construction, the Meadville Market House will soon be in the market for new doors. The current doors don't date back to the time of its construction in 1870, but they are believed to be more than 50 years old, according to Ashley Mattocks-Rose, who chairs the authority that oversees the Market House. 'We couldn't be more excited about it — new roof, new doors,' Mattocks Rose said in a phone interview Friday, recalling another grant announced in April that will provide $560,000 in funding for roof upgrades at the historic structure. 'We just really feel like we've got great momentum right now. It's a really exciting time for Meadville in general and for what the Market House means to Meadville.' The grant to the Market House was among 37 awards announced Thursday by the Pennsylvania Historical & Museum Commission (PHMC). The recipients were selected from a competitive pool of 114 applicants. Each award requires a local match equal to the amount of the grant, according to the announcement. Other recipients in the state's northwestern region included the Erie County historical society, which received $100,000 to repair 96 original wood-framed windows in the historic Watson-Curtze mansion. Venango County will receive $100,000 to replace its courthouse roof. Built in 1868, the building's slate roof is believed to date to approximately 1905. The Oil City Civic Center will receive $15,000 for a new security camera system "We are pleased to support these important projects from across the Commonwealth," said Andrea Lowery, PHMC executive director. "It is rewarding to impact communities in 15 counties. The selected projects beautifully showcase what historic resources Pennsylvanians value – from cornerstone buildings in their downtowns, like a historic market house and a significant industrial complex, to an historic barn. This investment ensures that Pennsylvania's cultural memory will be preserved for future generations." The Market House grant will be supplemented in part with about $15,000 raised through the facility's 2024 Crawford Gives campaign, which specifically highlighted the need for new doors, according to Mattocks-Rose. The Market Authority kicked off the campaign with a parody music video featuring Mattocks-Rose and friend Austin Kulyk. The video, which amassed 10,000 views in less than 24 hours, featured the two singers seated in the building's seated in the main market space with a Market House-themed takeoff of the song 'Love is an Open Door' from the Disney musical 'Frozen.' 'We really need new doors,' the duo sang in the video, which is no longer available on the Market House Facebook page. 'Help us replace our doooooors — historically accurate doors.' Mattocks-Rose said she didn't think the video was part of the authority's grant application, but said another video would likely be part of the strategy for the 2025 Crawford Gives event later this summer. The high cost of replacing the doors results from the need for custom fabrication of doors that are both historically appropriate and secure. Mattocks-Rose said a handicapped accessible entrance is also being considered for the building's northwest corner. A timeline for construction has not yet been determined. The building's 155-year history is the result of extended collective effort, according to Mattock-Rose, and the impending investments in the structure could set the stage for improvements in programming. 'It feels like now is the time to really just ramp this building up,' she said. 'Our job is to make sure that it's open for another 155 years.'
Yahoo
4 days ago
- Yahoo
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pursue other opportunities in the oncology space. Dr. Rose has dedicated his career to immunology translational medicine and advancing new treatment options for autoimmune patients. In various leadership roles, he has brought forward more than a dozen programs from discovery into clinical development, and he has developed multiple pioneering approved medicines such as Sotyktu, Stelara, and Tremfya. 'Dr. Rose joins the Nkarta team at a critical threshold as we discover the power of our NK cell platform to treat autoimmune diseases,' said Paul J. Hastings, CEO of Nkarta. 'He is an enterprise leader with a deep clinical background in rheumatology and immunology that's ideally suited to maximize the potential of our allogeneic NK cell platform. Shawn's proven track record as an expert clinician gives me full confidence that he will hit the ground running on day one and meaningfully advance our work in the clinic.' Dr. Rose most recently served as Chief Development Officer, Immunology, at Vividion Therapeutics, working to expand their portfolio by advancing previously undruggable targets in immunology. He also served as interim CMO and Head of Clinical Development at Magenta Therapeutics, working on cell-based therapeutic approaches for patients with cancer, genetic disorders and immune-mediated inflammatory diseases. Dr. Rose also held multiple clinical and development leadership roles at Annexon Biosciences, Janssen Pharmaceuticals, and Bristol-Myers Squibb. He did his postdoctoral research training and clinical training in Internal Medicine and Rheumatology at the Northwestern University Feinberg School of Medicine. 'I am thrilled to join Nkarta to advance innovative cell therapies for patients,' said Dr. Rose. 'I strongly believe that Nkarta's allogeneic NK cell platform has the potential to be a transformational approach for patients with immune-mediated inflammatory disease. I look forward to working closely with Paul and the broader Nkarta team on developing more treatment options for patients.' During the transition, Dr. Rose will work with Dr. Shook, who will remain on as a consultant through July 11. 'Dave was an early pioneer of NK cell therapy while working under Nkarta's scientific founder, Dario Campana, at St. Jude Children's Research Hospital, and he has tirelessly pursued options that were more convenient for patients with safety utmost in mind,' Hastings said. 'Dave has devoted much of his career to make important contributions to the advancement of natural killer cell therapy, leading our early clinical work in cancer and overseeing key aspects of our strategic shift into a new disease area with agility and flexibility. But Dave is a dedicated oncologist, and he has decided to return to the field he loves. He is a fearless advocate for patients and their well-being and a very good friend who will be missed.' About NKX019NKX019 is an allogeneic, cryopreserved, off-the-shelf immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors. It is engineered with a humanized CD19-directed chimeric antigen receptor (CAR) for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Nkarta is evaluating NKX019 in multiple autoimmune conditions. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company's website at Cautionary Note on Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," 'plans,' 'potential,' "projects,' 'would' and "future" or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include, but are not limited to, statements concerning Nkarta's expectations regarding any or all of the following: Nkarta's position, plans, strategies, and timelines for the continued and future clinical development and commercial potential of NKX019 (including the future availability and disclosure of clinical data and other updates from Nkarta's clinical trials). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Nkarta's limited operating history and historical losses; Nkarta's lack of any products approved for sale and its ability to achieve profitability; the risk that the results of preclinical studies and early-stage clinical trials may not be predictive of future results; Nkarta's ability to raise additional funding to complete the development and any commercialization of its product candidates; Nkarta's dependence on the clinical success of NKX019; that Nkarta may be delayed in initiating, enrolling patients in or completing its clinical trials; competition from third parties that are developing products for similar uses; Nkarta's ability to obtain, maintain and protect its intellectual property; Nkarta's dependence on third parties in connection with manufacturing, clinical trials and pre-clinical studies; the complexity of the manufacturing process for CAR NK cell therapies; and the success of Nkarta's recent (and any future) cost containment measures. These and other risks and uncertainties are described more fully in Nkarta's filings with the Securities and Exchange Commission ('SEC'), including the 'Risk Factors' section of Nkarta's Annual Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 14, 2025, and Nkarta's other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Nkarta undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Nkarta Media/Investor Contact:Nadir MahmoodNkarta, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
